Linnea SA ’s Post

💊 𝗧𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗱𝗿𝘂𝗴 𝘀𝗮𝗳𝗲𝘁𝘆: 𝗽𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗻𝗴 𝗻𝗶𝘁𝗿𝗼𝘀𝗮𝗺𝗶𝗻𝗲 𝗰𝗼𝗻𝘁𝗮𝗺𝗶𝗻𝗮𝘁𝗶𝗼𝗻 As we advance in pharmaceutical sciences, the focus intensifies on preventing contaminants like nitrosamines. Emiliano De Dominicis and Sergio Fasan are firmly convinced that Mérieux NutriSciences - Italia advanced technologies can guarantee safer drugs on the market.   𝗦𝗼, 𝘄𝗵𝗮𝘁’𝘀 𝗻𝗲𝘄 𝗶𝗻 Mérieux NutriSciences - Italia? It has been fully validated a suitable high sensitivity method for 𝗡-𝗡𝗶𝘁𝗿𝗼𝘀𝗼-𝗖𝗶𝗻𝗻𝗮𝗿𝗶𝘇𝗶𝗻𝗲 𝗜𝗺𝗽𝘂𝗿𝗶𝘁𝘆 𝗔 (𝗡𝗖𝗜𝗡) 𝗼𝗻 𝘁𝗮𝗯𝗹𝗲𝘁𝘀 through 𝗨𝗛𝗣𝗟𝗖-𝗠𝗦/𝗠𝗦 𝘄𝗶𝘁𝗵 𝗟𝗢𝗤 𝟮,𝟮 𝗽𝗽𝗯.   ➡ 𝗡𝗲𝘄 𝘃𝗮𝗹𝗶𝗱𝗮𝘁𝗲𝗱 𝗺𝗲𝘁𝗵𝗼𝗱 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲! Do not hesitate to send me a message to ask your questions!   #Mxns #Pharmaceuticals #Nitrosamines #DrugSafety

Medical cannabis and bio-products businesses handle starting materials for active pharmaceutical ingredients. Traceability is essential for these businesses to track and trace every stage of production, to ensure compliance, streamline operations, and better allocate resources. Implementing traceability from the start is vital for new businesses, where planning before starting cultivation can ensure the facility, equipment, and process design are suited for handling traceability. Here’s Fanis Vassiliou, Technical Director at Q-CERT SA - Certification Body - one of Europe’s largest certification bodies based in Greece, sharing his insights on the importance of incorporating traceability from the inception of a cannabis business. Yogesh Jhamtani #Cannabis #CannabisIndustry #CannabisBusiness #CBD #MedicalCannabis #HempIndustry #Pharmaceuticals #PharmaIndustry #Pharma #CannabisConsulting #GACP #GMP #EUGMP #Europe #Greece

⏰ The Jordan Food and Drug Administration (JFDA) has extended the deadline for implementing DataMatrix code and serialization on regulated pharmaceutical products' secondary packaging until 30 June 2024, according to a new circular. Find more information by clicking on our article on Jordanian pharma serialization 👉 https://lnkd.in/e3EEjzpC #Jordan #JFDA #pharmaserialization

Do you need support defining the impurity profile of your active pharmaceutical ingredient (API) or drug product? 🔎 Impurities can arise from different aspects of drug development including synthesis, degradation, and formulation. To confidently produce a safe final drug product, all possible impurities must be identified, according to regulatory requirements. 💡Find out more and get in touch for expert guidance: https://ow.ly/3cfe50QIX13. #ChemicalSafety #DrugDevelopment #PharmaSafety #RiskAssessment #ConsultLhasa

We use Lhasa Limited software and our expertise to provide the best risk assessments and regulatory support tailored to your needs. Get in touch! #riskassessment #impurities #consulting #regulatoryaffairs

When discussing impurities in medicinal products, it is important to note that active pharmaceutical ingredients and medicinal products are seldom without any trace of impurities – there is always a minute amount of contamination. Yuri Ceragioli, MS, explains more in this first of a series focused on regulatory management of impurities, in which he introduces the topic of impurities in drug substances and drug products from a regulatory chemistry, manufacturing, and controls perspective in this Regulatory Focus peer-reviewed article: https://bit.ly/4aFYvzA

#Pharmaceutical #QbD #Drug-Device #Combination #Products o QbD achieves quality through understanding of all components and processes, with a detailed understanding of risks and how they can be mitigated. o High-quality packaging components and delivery systems significantly contribute to patient safety. As a result of concerns for risk to patients, the U.S. Food and Drug Administration (FDA) and other regulatory agencies around the world are requiring drug makers to develop and institute improved quality processes in the manufacturing of drug products and their container closure and delivery systems. 

It was a pleasure to visit the Jiangsu Food and Drug Inspection Institute in Nanjing to discuss recent trends in pharmaceutical excipients. I am convinced that in order to bring game-changing innovations to patients we need a closer interaction between excipients providers, pharmaceutical companies and regulatory bodies. After an extensive and far-reaching discussion with our friends in Jiangsu, we are already embarking on this path and will continue the discussion on how we can work together to enable the technologies of the future for oral solid dosage forms! Big thanks to our team in China for organizing such a rewarding and productive session! #regulatory #pharma #nextgentech

📣 The 63rd edition of the 𝐀𝐅𝐈 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦 is a week away! This prestigious Italian conference has been bringing together international stakeholders in the pharmaceutical sector for over 60 years.   Join us in Rimini, from June 5th to 7th, at 𝐛𝐨𝐨𝐭𝐡 𝟳𝟳.   Our experts are eager to discuss how we can support you with product formulation and active ingredient testing, as well as 𝐟𝐢𝐥𝐭𝐞𝐫 𝐚𝐧𝐝 𝐩𝐫𝐨𝐜𝐞𝐬𝐬 𝐯𝐚𝐥𝐢𝐝𝐚𝐭𝐢𝐨𝐧.   ⬇️ Discover more at the link in the first comment! #highqualitycontrols #commitment2innovation #processvalidation #pharma #afi

Control of Impurities: EDQM CEP Approach Sharing a valuable presentation from the EDQM Virtual Training Programme on controlling impurities in pharmaceuticals. Topics include: Managing organic, mutagenic, and nitrosamine impurities Setting API specifications Case studies like Omeprazole Sodium #Pharmaceuticals #QualityControl #Impurities #EDQM #CEP #regulatory #pharma #sfda #gcc #eda #middleeast